This Article Full Text Full Text (PDF) CME: Take the course for this article: Prognostic and Predictive Factors in Early-Stage Breast Cancer eLetters: Submit a response to this article Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Cianfrocca, M. Articles by Goldstein, L. J. Search for Related Content PubMed PubMed Citation Articles by Cianfrocca, M. Articles by Goldstein, L. J.

Prognostic and Predictive Factors in Early-Stage Breast Cancer

Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA

Correspondence: Mary Cianfrocca, D.O., Fox Chase Cancer Center, 333 Cottman Ave, Philadelphia, Pennsylvania 19111, USA. Telephone: 215-728-2974; Fax: 215-728-3639; e-mail: M_Cianfrocca{at}fccc.edu

Breast cancer is the most common malignancy among American women. Due to increased screening, the majority of patients present with early-stage breast cancer. The Oxford Overview Analysis demonstrates that adjuvant hormonal therapy and polychemotherapy reduce the risk of recurrence and death from breast cancer. Adjuvant systemic therapy, however, has associated risks and it would be useful to be able to optimally select patients most likely to benefit. The purpose of adjuvant systemic therapy is to eradicate distant micrometastatic deposits. It is essential therefore to be able to estimate an individual patient’s risk of harboring clinically silent micrometastatic disease using established prognostic factors. It is also beneficial to be able to select the optimal adjuvant therapy for an individual patient based on established predictive factors. It is standard practice to administer systemic therapy to all patients with lymph node-positive disease. However, there are clearly differences among node-positive women that may warrant a more aggressive therapeutic approach. Furthermore, there are many node-negative women who would also benefit from adjuvant systemic therapy. Prognostic factors therefore must be differentiated from predictive factors. A prognostic factor is any measurement available at the time of surgery that correlates with disease-free or overall survival in the absence of systemic adjuvant therapy and, as a result, is able to correlate with the natural history of the disease. In contrast, a predictive factor is any measurement associated with response to a given therapy. Some factors, such as hormone receptors and HER2/neu overexpression, are both prognostic and predictive.

Key Words. Breast cancer • Prognostic factors • Predictive factors • Adjuvant therapy

This article has been cited by other articles:

				L. B. Michaud Treatment-experienced breast cancer Am. J. Health Syst. Pharm., May 15, 2008; 65(10_Supplement_3): S4 - S9. [Abstract] [Full Text] [PDF]

				X.-J. Ma, R. Salunga, S. Dahiya, W. Wang, E. Carney, V. Durbecq, A. Harris, P. Goss, C. Sotiriou, M. Erlander, et al. A Five-Gene Molecular Grade Index and HOXB13:IL17BR Are Complementary Prognostic Factors in Early Stage Breast Cancer Clin. Cancer Res., May 1, 2008; 14(9): 2601 - 2608. [Abstract] [Full Text] [PDF]

				M. Kyndi, F. B. Sorensen, H. Knudsen, M. Overgaard, H. M. Nielsen, and J. Overgaard Estrogen Receptor, Progesterone Receptor, HER-2, and Response to Postmastectomy Radiotherapy in High-Risk Breast Cancer: The Danish Breast Cancer Cooperative Group J. Clin. Oncol., March 20, 2008; 26(9): 1419 - 1426. [Abstract] [Full Text] [PDF]

				S. Dawood, K. Broglio, A. M. Gonzalez-Angulo, S.-W. Kau, R. Islam, G. N. Hortobagyi, and M. Cristofanilli Prognostic Value of Body Mass Index in Locally Advanced Breast Cancer Clin. Cancer Res., March 15, 2008; 14(6): 1718 - 1725. [Abstract] [Full Text] [PDF]

				S. Dawood, K. Broglio, S.-W. Kau, R. Islam, W. F. Symmans, T. A. Buchholz, S. E. McGuire, F. Meric-Bernstam, M. Cristofanilli, G. N. Hortobagyi, et al. Prognostic Value of Initial Clinical Disease Stage After Achieving Pathological Complete Response Oncologist, January 1, 2008; 13(1): 6 - 15. [Abstract] [Full Text] [PDF]

				C. G. Jakobsen, N. Rasmussen, A.-V. Laenkholm, and H. J. Ditzel Phage Display Derived Human Monoclonal Antibodies Isolated by Binding to the Surface of Live Primary Breast Cancer Cells Recognize GRP78 Cancer Res., October 1, 2007; 67(19): 9507 - 9517. [Abstract] [Full Text] [PDF]

				H. S. Bachmann, F. Otterbach, R. Callies, H. Nuckel, M. Bau, K. W. Schmid, W. Siffert, and R. Kimmig The AA Genotype of the Regulatory BCL2 Promoter Polymorphism ( 938C>A) Is Associated with a Favorable Outcome in Lymph Node Negative Invasive Breast Cancer Patients Clin. Cancer Res., October 1, 2007; 13(19): 5790 - 5797. [Abstract] [Full Text] [PDF]

				H. Abe, R. A. Schmidt, C. A. Sennett, A. Shimauchi, and G. M. Newstead US-guided Core Needle Biopsy of Axillary Lymph Nodes in Patients with Breast Cancer: Why and How to Do It RadioGraphics, October 1, 2007; 27(suppl_1): S91 - S99. [Abstract] [Full Text] [PDF]

				O. Tacca, F. Penault-Llorca, C. Abrial, M.-A. Mouret-Reynier, I. Raoelfils, X. Durando, J.-L. Achard, P. Gimbergues, H. Cure, and P. Chollet Changes in and Prognostic Value of Hormone Receptor Status in a Series of Operable Breast Cancer Patients Treated with Neoadjuvant Chemotherapy Oncologist, June 1, 2007; 12(6): 636 - 643. [Abstract] [Full Text] [PDF]

				J. T. Jorgensen, K. V. Nielsen, and B. Ejlertsen Pharmacodiagnostics and Targeted Therapies--A Rational Approach for Individualizing Medical Anticancer Therapy in Breast Cancer Oncologist, April 1, 2007; 12(4): 397 - 405. [Abstract] [Full Text] [PDF]

				S. Sarp, G. Fioretta, H. M. Verkooijen, G. Vlastos, E. Rapiti, H. Schubert, A.-P. Sappino, and C. Bouchardy Tumor Location of the Lower-Inner Quadrant Is Associated with an Impaired Survival for Women With Early-Stage Breast Cancer Ann. Surg. Oncol., March 1, 2007; 14(3): 1031 - 1039. [Abstract] [Full Text] [PDF]

				L Wang, L Peng, B Dong, L Kong, L Meng, L Yan, Y Xie, and C Shou Overexpression of phosphatase of regenerating liver-3 in breast cancer: association with a poor clinical outcome Ann. Onc., October 1, 2006; 17(10): 1517 - 1522. [Abstract] [Full Text] [PDF]